New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2013
05:55 EDTUBS, UBS, LAZ, LAZ, ED, ED, BLK, BLK, MRK, MRK, T, T, NYX, NYX, CPB, CPB, HES, HES, JNJ, JNJ, INTC, INTC, AA, AA, SAN, SANCapital Link to host a forum
Annual CSR Forum: CSR & IR--Maximizing Shareholder Value will be held in New York on March 13.
News For UBS;AA;INTC;JNJ;HES;CPB;NYX;T;MRK;BLK;ED;LAZ;SAN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 >>
January 25, 2016
16:11 EDTEDConsolidated Edison creates new transmission subsidiary
Subscribe for More Information
16:00 EDTTOptions Update; January 25, 2016
Subscribe for More Information
14:40 EDTTAT&T volatility elevated into Q4 and outlook
AT&T January weekly call option implied volatility is at 30, February is at 18; compared to its 52-week range of 13 to 27, suggesting large near term price movement into the expected release of Q4 results on January 26.
14:29 EDTJNJNotable companies reporting before tomorrow's open
Subscribe for More Information
14:19 EDTTAT&T technical notes before earnings
The key support level for the shares is at $32.50, the bottom of its trading range for the most part since February 2014. If the news is negative, the $32.50 area could be tested. A breakdown below that level would be a technical negative, voiding years of support. Next downside objectives would then be at $31.52 and $30.54. If the news is a positive surprise, there is long-run level of resistance at $37 that would be the first big upside test. A move above $37 would resolve a nearly 2-year long trading range bullishly. Next resistance would be at $37.86.
12:42 EDTJNJEarnings Watch: J&J shares little changed since last earnings report
Johnson & Johnson (JNJ) is scheduled to report fourth quarter earnings before the market opens on Tuesday, January 26, with a conference call scheduled for 8:30 am ET. Johnson & Johnson is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. EXPECTATIONS: Analysts are looking for earnings per share of $1.42 on revenue of $17.88B, according to First Call. The consensus range for EPS is $1.39-$1.44 on revenue of $17.57B-$18.31B. LAST QUARTER: On October 13, Johnson & Johnson reported third quarter EPS of $1.49 on revenue of $17.1B. The company's Q3 EPS results exceeded average analyst expectations of $1.45 but its revenue came in less than analysts' expectations of $17.54B. With its Q3 results, the drug giant narrowed its EPS view for the year to $6.15-$6.20 from $6.10-$6.20, while maintaining its sales outlook of $75B-$76B. Worldwide Consumer sales of $3.3B for Q3 represented a decrease of 7.7% versus the prior year, consisting of an operational increase of 3.1% and a negative impact from currency of 10.8%. Worldwide Pharmaceutical sales of $7.7B for the third quarter represented a decrease of 7.4% versus the prior year with an operational decrease of 0.3% and a negative impact from currency of 7.1%. Domestic sales decreased 4.5%; international sales decreased 11.1%, which reflected an operational increase of 5.5% and a negative currency impact of 16.6%. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 10.1%, domestic sales increased 11.5% and international sales increased 8.5%. Worldwide operational sales growth was driven by new products and the strength of core products. New product sales growth was negatively impacted by lower sales of Olysio/Sovriad due to competitive entrants. Strong growth in new products include Invokana/Invokamet, for the treatment of adults with type 2 diabetes; Imbruvica, an oral, once-daily therapy approved for use in treating certain B-cell malignancies, or blood cancers; Xarelto, an oral anticoagulant; and Zytiga, an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer. On January 19, Johnson & Johnson announced restructuring actions in its Medical Devices unit. The actions are expected to result in annualized pre-tax cost savings of $800M to $1B, the majority of which is expected to be realized by the end of 2018, including approximately $200M in 2016. With its restructuring announcement the company reiterated its prior adjusted EPS view of $6.15- $6.20. STREET RESEARCH: On December 18, Atlantic Equities analyst Steve Chesney initiated Johnson & Johnson with a Neutral rating and $95 price target. On December 1, Barclays analyst Geoff Meacham upgraded Johnson & Johnson to Overweight after assuming coverage of the name. J&J should post a strong year in 2017 and will likely boost its orphan diseases or oncology pipeline via capital deployment, Meacham tells investors in a research note. He raised his price target for shares to $115 from $101. PRICE ACTION Since reporting its Q3 results, Johnson & Johnson shares are up approximately 1%, and they are currently trading up fractionally in afternoon trading ahead of Tuesday's earnings report.
12:17 EDTJNJJohnson & Johnson technical notes before earnings
The key level for the shares heading into earnings is at the $90 to $88 area, which has been a zone of support since late 2013. If the news is bearish, shares could retest this area. A breakdown below $90 would confirm a long-term topping process is underway. If the news is bullish, the first important resistance level is at the $100 area. A breakout above $100 would put the 52-week high at $105.49 up as the next major upside objective.
10:21 EDTEDSupreme Court upholds FERC 'demand response' rule
Subscribe for More Information
09:32 EDTINTCApple Active equity options trading on open
Subscribe for More Information
09:30 EDTAAElliott boosts activist stake in Alcoa to over 7%
Paul Singer's Elliott Associates boosted its activist stake in Alcoa to 7.4% from the 6.4% position the hedge fund reported on November 23. Elliott, in today's filing with the SEC, reiterated its belief that the spin-off transaction recently announced by Alcoa "will create value substantially above the current share price." The hedge fund seeks to "engage in a constructive dialogue" with the company's board and management regarding the transaction "as well as a number of other additional available opportunities to maximize shareholder value."
09:08 EDTTAutoZone to deploy AT&T services at its locations in the U.S.
Subscribe for More Information
09:04 EDTTSprint doubles number of LTE Plus markets
Subscribe for More Information
09:03 EDTMRKOn The Fly: Pre-market Movers
HIGHER: Tyco (TYC) and Johnson Controls (JCI), up 9% and 1%, respectively, after announcing a definitive merger agreement. Johnson Controls shareholders will own approximately 56% of the equity of the combined company, while current Tyco shareholders will own approximately 44%... SunEdison (SUNE), up 10% after the Wall Street Journal reported that the company is set to give David Einhorn's Greenlight Capital a seat on its board... Affimed Therapeutics (AFMD), up 26% after entering a clinical research collaboration in immuno-oncology with Merck (MRK). UP AFTER EARNINGS: McDonald's (MCD), up 3%... LOWER: Twitter (TWTR), down 5% after its CEO Jack Dorsey confirmed in a tweet last night that several executives are departing the company. Media reports also indicate that, as part of its shake-up, Twitter intends to bring in two new members to its board as soon as this week... OncoMed (OMED), down 38% after an independent data safety monitoring board remarked on several findings regarding futility of the company's Phase 2 ALPINE clinical trial... Medivation (MDVN), down 7% after FDA places investigational new drug application for MDV9300 on partial clinical hold... International Paper (IP), down 4.8%, Packaging Corp. (PKG), down 4.8%, WestRock (WRK), down 6%, after Pulp & Paper Week reduced January kraftliner and corrugated medium prices... Caterpillar (CAT), down 4% after Goldman cuts rating to sell... Regeneron (REGN), down 3% after downgraded at Chardan to sell. DOWN AFTER EARNINGS: Kimberly-Clark (KMB), down 2.5%.
07:59 EDTHESHess Corp. price target lowered to $38 from $58 at JPMorgan
Subscribe for More Information
07:16 EDTINTCIntel upgraded to Outperform from Neutral at Macquarie
Macquarie analyst Deepon Nag upgraded Intel to Oupterform and raised his price target to $35 from $34 on shares. The analyst believes the combination of easier comps and moderating competition in tablets and smartphones should result in a PC shipment growth acceleration into CY16. Additionally, Nag said Intel has been undershipping end-demand for all of 2015, which adds to estimates and potential upside as the PC supply chain replenishes inventories.
06:53 EDTJNJGlaxo, Astra, J&J partner with universities in drug research fund, Reuters says
Subscribe for More Information
05:36 EDTINTCStocks with implied volatility below IV index mean; CELG INTC
Subscribe for More Information
05:19 EDTMRKAffimed Therapeutics enters into collaboration with Merck
Subscribe for More Information
January 24, 2016
19:15 EDTSANBanco Santander denies interest in Montei dei Paschi, Reuters says
Subscribe for More Information
18:28 EDTTAT&T potentially circling Time Warner, New York Post says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use